FdaApplication
NDA 215431
Identifiers
- fda_app_no: NDA215431
Properties
| Property | Value |
|---|---|
| applicant_name | AXSOME THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2025-01-30 |
Revenue by product
SYMBRAVO
| Period | Revenue |
|---|---|
| Q2 2026 | $2.3M |
| Q1 2026 | $4.1M |
| Q3 2025 | $2.1M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SYMBRAVO | MELOXICAM; RIZATRIPTAN BENZOATE | 20MG;EQ 10MG BASE | TABLET;ORAL |
1 product